Products for Research Use Only

BD-1047 (dihydrobromide)

CAT: 0804-HY-16996A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16996A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors. BD-1047 dihydrobromide attenuates Apomorphine -induced climbing and Phencyclidine-induced head twitches[1].
CAS Number
138356-21-5
UNSPSC
12352005
Hazard Statement
H315, H318, H335
Target
Sigma Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/BD-1047-dihydrobromide.html
Purity
98.45
Solubility
DMSO : 25 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)
Smiles
CN(C)CCN(CCC1=CC=C(Cl)C(Cl)=C1)C.[H]Br.[H]Br
Molecular Formula
C13H22Br2Cl2N2
Molecular Weight
437.04
Precautions
H315, H318, H335
References & Citations
[1]Skuza G, et al. Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity. Pharmacol Rep. 2006 Sep-Oct;58 (5) :626-35.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Sigma 1 Receptor
Citation 01
Behav Brain Res. 2025 Apr 27:484:115493.|Cell Rep. 2023 Jan 31;42 (1) :112011.|Eur J Med Res. 2025 Oct 30;30 (1) :1041.|Eur J Pharmacol. 2023 May 5:946:175647.|Int Immunopharmacol. 2023 Apr:117:109907.|Int Immunopharmacol. 2024 Jan 25:127:111382.|Int J Gen Med. 2025 Apr 4:18:1917-1931.|Mol Med. 2022 Aug 3;28 (1) :87.|Neural Regen Res. 2024 Apr 3.|Life Sci. 2020 Sep 15;257:118047.|Mol Neurobiol. 2025 Jun 1.